Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial To Evaluate The Safety Of CK0801 In Treatment-Resistant Guillain-Barré Syndrome (GBS)

NCT03773328 is registered in ClinicalTrials.gov with Cellenkos, Inc. as lead sponsor.

NCT NCT03773328
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03773328 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial To Evaluate The Safety Of CK0801 In Treatment-Resistant Guillain-Barré Syndrome (GBS)
Lead sponsor
Cellenkos, Inc.
Phase
Phase 1
Overall status
Withdrawn
Start date
November 30, 2022
Completion date
February 28, 2027
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

guillain-barré syndrome